1. Bioanalysis of isoniazid;Agrawal,1999
2. Ahlburg, D.A., 2000. The economic impacts of tuberculosis: Stop TB initiative 2000 series. WHO/CDS/STB/2000.5. World Health Organization, Geneva.
3. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis;Blomberg;Bull. WHO,2001
4. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption;Ellard;Int. J. Tuberc. Lung Dis.,1999
5. Fourie, B., Pillai, G., Mcllleron, H., Smith, P., Panchagnula, R., Ellard, G., 1999. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol), WHO/CDS/TB/99.274, 1999, World Health Organization, Geneva.